You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 23, 2024

Claims for Patent: 10,030,051

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,030,051

Title:	Antibody targeting through a modular recognition domain
Abstract:	The present invention provides antibodies containing one or more modular recognition domains (MRDs) for targeting the antibodies to specific sites. The use of the antibodies containing one or more modular recognition domains to treat disease, and methods of making antibodies containing one or more modular recognition domains are also provided in the invention.
Inventor(s):	Barbas, III; Carlos F. (La Jolla, CA)
Assignee:	The Scripps Research Institute (La Jolla, CA)
Application Number:	14/963,722
Patent Claims:	1. An antibody fusion protein comprising a full length antibody and a modular recognition domain (MRD), wherein the MRD binds to integrin and consists of the amino acid sequence set forth in any one of SEQ ID NOs: 3-6, wherein the MRD is operably linked to the antibody, and wherein the antibody binds to ErbB2. 2. The antibody fusion protein of claim 1, wherein the antibody and the MRD are operably linked through a linker peptide. 3. The antibody fusion protein of claim 2, wherein the linker peptide comprises a sequence selected from the group consisting of: GGGS (SEQ ID NO: 1), SSGGGGSGGGGGGSS (SEQ ID NO: 2), and SSGGGGSGGGGGGSSRSS (SEQ ID NO: 19). 4. The antibody fusion protein of claim 1, wherein the MRD is operably linked to the C-terminal end of the heavy chain of the antibody, the N-terminal end of the heavy chain of the antibody, the C-terminal end of the light chain of the antibody, or the N-terminal end of the light chain of the antibody. 5. The antibody fusion protein of claim 1, wherein the antibody is a chimeric or humanized antibody. 6. The antibody fusion protein of claim 1, wherein the antibody is Trastuzumab. 7. The antibody fusion protein of claim 2, wherein the antibody is a chimeric or humanized antibody. 8. The antibody fusion protein of claim 2, wherein the antibody is Trastuzumab. 9. A method of treating a disease characterized by undesired angiogenesis, comprising administering to a subject in need thereof the antibody fusion protein of claim 1.

Details for Patent 10,030,051

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998	⤷ Try a Trial	2028-01-03
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017	⤷ Try a Trial	2028-01-03
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019	⤷ Try a Trial	2028-01-03
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.